Circulating endothelial progenitor cells in gynaecological cancer
- Authors
- Kim, Yoon Byoung; Chung, Ye Won; Bae, Hyo Sook; Lee, Jae Kwan; Lee, Nak Woo; Lee, Kyu Wan; Song, Jae Yun
- Issue Date
- 4월-2013
- Publisher
- SAGE PUBLICATIONS LTD
- Keywords
- Cervical cancer; CD34(+); CD45(-); CD133(+); circulating endothelial progenitor cells; ovarian cancer; VEGFR2(+)
- Citation
- JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, v.41, no.2, pp.293 - 299
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
- Volume
- 41
- Number
- 2
- Start Page
- 293
- End Page
- 299
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/103544
- DOI
- 10.1177/0300060513476999
- ISSN
- 0300-0605
- Abstract
- Objectives: To compare the frequency and absolute numbers of circulating endothelial progenitor cells (EPCs) in healthy control subjects and patients with gynaecological cancer, and to test the hypothesis that cancer treatment lowers EPC numbers. Methods: Patients with cervical or ovarian cancer and healthy control subjects provided peripheral blood samples for the isolation of mononuclear cells. EPCs were identified by quadruple immunofluorescence staining and flow cytometry as CD45(-)/CD34(+)/CD133(+)/vascular endothelial growth factor receptor 2 (VEGFR2)(+) cells. Results: In total, 28 participants were enrolled. Circulating EPCs were present at higher frequencies (and in greater absolute numbers) in patients with cervical or ovarian cancer (n = 14) than in controls (n = 14). Concurrent chemoradiation therapy or surgery significantly reduced the frequency and number of EPCs in patients with gynaecological cancer, compared with pretreatment levels. Conclusions: EPC levels decline throughout cancer treatment; their measurement may therefore be a useful surrogate marker to monitor treatment response.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.